Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0461929603
Thu, 20.04.2023
Xlife Sciences AG
Xlife Sciences AG (SIX: XLS) today reported its 2022 results and 2023 outlook. The company also published the independent valuation report covering its project portfolio as of December 31, 2022.
Operational progress in 2022
As at December 31, 2022, Xlife Sciences had 26 project companies. Among other things, they made the following pleasing progre [ … ]
Thu, 20.04.2023
Xlife Sciences AG
Xlife Sciences AG (SIX: XLS) today reported its 2022 results and 2023 outlook. The company also published the independent valuation report covering its project portfolio as of December 31, 2022.
Operational progress in 2022
As at December 31, 2022, Xlife Sciences had 26 project companies. Among other things, they made the following pleasing progre [ … ]
Thu, 16.02.2023
Xlife Sciences AG
Medical Screening Device Set to Measure Complex Neurocognitive Performance for Early Detection of Severe Neurodegenerative Diseases Such as Parkinson's or Alzheimer's
saniva diagnostics, a portfolio company of Xlife Sciences (SIX: XLS), has received the 513(g) approval from the US Food and Drug Administration (FDA) to market and sell its proprietar [ … ]
Thu, 16.02.2023
Xlife Sciences AG
Medical Screening Device Set to Measure Complex Neurocognitive Performance for Early Detection of Severe Neurodegenerative Diseases Such as Parkinson's or Alzheimer's
saniva diagnostics, a portfolio company of Xlife Sciences (SIX: XLS), has received the 513(g) approval from the US Food and Drug Administration (FDA) to market and sell its proprietar [ … ]
Mon, 21.11.2022
Xlife Sciences AG
The Board of Directors of Xlife Sciences AG (SIX: XLS), a leading European life sciences incubator and accelerator based in Switzerland, has initiated a process to review strategic options, aimed at accelerating the company's business development, and increasing value for its stakeholders. This review will consider all options available to the comp [ … ]
Mon, 21.11.2022
Xlife Sciences AG
The Board of Directors of Xlife Sciences AG (SIX: XLS), a leading European life sciences incubator and accelerator based in Switzerland, has initiated a process to review strategic options, aimed at accelerating the company's business development, and increasing value for its stakeholders. This review will consider all options available to the comp [ … ]
Wed, 28.09.2022
Xlife Sciences AG
Xlife Sciences (SIX: XLS) today published its results for the first half of 2022 ending 30 June 2022. Oliver R. Baumann, CEO Xlife Sciences, comments: “In implementing our strategy of bridging preclinical research & development to healthcare markets, we have achieved relevant steps despite a challenging market environment and can look back on s [ … ]
Wed, 28.09.2022
Xlife Sciences AG
Xlife Sciences (SIX: XLS) today published its results for the first half of 2022 ending 30 June 2022. Oliver R. Baumann, CEO Xlife Sciences, comments: “In implementing our strategy of bridging preclinical research & development to healthcare markets, we have achieved relevant steps despite a challenging market environment and can look back on s [ … ]
Mon, 09.05.2022
Xlife Sciences AG
Xlife Sciences AG (SIX: XLS) today for the first time published an independent assessment of its project portfolio and intends to issue this report annually from now on.
The extensive Valuation Report as of December 31, 2021 identified a valuation range of CHF 574 million up to CHF 701 million. The average value of this range corresponds to more t [ … ]
Fri, 29.04.2022
Xlife Sciences AG
Highlights 2021:
Successful exit of a project company through the initial public offering of Vitruvia Medical on the Stock Exchange in Munich (unregulated market ['Freiverkehr']. Vitruvia Medical develops innovative circulatory systems for very complex medical devices, in particular robot-assisted surgery. Around 60 percent of the ongoing projec [ … ]